DBV Technologies SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Edison Investment Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
DBV Technologies announces first reported case of long term sustained effect of peanut desensitization after Epicutaneous Immunotherapy (EPIT) with Viaskin
DBV Technologies SA:Says Dr Thierry Bourrier and Professor Christophe Dupont presented abstract showing that peanut-allergic child from ARACHILD study had sustained desensitization even after one year off treatment.Abstract highlights eight-year-old patient from ARACHILD trial, who voluntarily stopped EPIT treatment after reaching 1,146mg peanut protein (4 to 5 peanuts) during 18-month food challenge, from 96'33 mg peanut protein at entry (1/3 peanut).After 12 months of no treatment and following strict non-peanut diet, child performed another food challenge and was able to reach again cumulative reactive dose of 1,110 mg peanut protein.
Latest Developments for DBV Technologies SA
- DBV Technologies announces proposed global offering for 2.67 mln shares
- DBV Technologies SA announces primary endpoint met in VIPES, Viaskin Peanut's Phase IIb clinical trial in peanut allergy
- DBV Technologies SA files IPO - Form F-1
- DBV Technologies presents preclinical data to support DBV`s EPITTM disease modifying effect
- Share this
- Digg this